Opportunities in times of change: RIGHT TIME, RIGHT NOW
The Life Sciences sector in India is facing unprecedented change, driven by a convergence of demographic growth, urbanization, digitization, and a continued push on financial inclusion. At the same time, the evolving regulatory regime in price control, generic drugs, and the implementation of GST has brought healthcare stakeholders back to the drawing board.

The past year has been challenging for Indian generic companies from an export perspective as well. Price erosion, coupled with regulatory activism and protectionism has significantly impacted export revenues and margins What strategies should companies deploy to take on this rapid pace of change? How will healthcare stakeholders work together in ever more innovative ways to develop new models for distribution and healthcare delivery? Why is this the right time and what opportunities exist right now for the Life Sciences value chain? Be a part of the discussion at the 15th edition of BioAsia.